Home LiteratureArticle Details
PMID: 6799548 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

The Journal of clinical investigation ·Vol. 69 ·No. 2 ·1982-02-00 ·Pages 303-8

Pier GB

Abstract

The safety and immunogenicity of a high molecular weight polysaccharide from immunotype 1 Pseudomonas aeruginosa were tested in a dose response fashion in adult volunteers. The vaccine lacked toxicity and pyrogenicity for experimental animals. Doses of 50, 75, 150, or 250 microgram were given to groups of individuals as a single dose subcutaneous injection. Doses of 150 and 250 microgram were associated with a significant rise in binding and opsonic antibody at 2 wk postimmunization. Titers remained unchanged for up to 6 mo. The vaccine was almost devoid of toxicity, eliciting no more than a slightly sore and tender arm at the site of injection. High molecular weight polysaccharide antigen appears to induce a good immune response following vaccination that is effective in mediating opsonophagocytic killing of live P. aeruginosa organisms.

MeSH Terms
Animals Antibodies, Bacterial/biosynthesis Antigens, Bacterial/analysis,immunology Bacterial Vaccines/immunology,standards,toxicity Guinea Pigs Horseshoe Crabs/immunology Humans Molecular Weight Opsonin Proteins/immunology Polysaccharides, Bacterial/immunology,standards Pseudomonas aeruginosa/immunology Serotyping
Chemicals
Antibodies, Bacterial Antigens, Bacterial Bacterial Vaccines Opsonin Proteins Polysaccharides, Bacterial
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Pier G B
References (17)
17 references, click to expand
  1. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.
    Lancet. 1980 Dec 13;2(8207):1263-5 PMID: 6108445
  2. Correlation of the biologic responses of C3H/HEJ mice to endotoxin with the chemical and structural properties of the lipopolysaccharides from Pseudomonas aeruginosa and Escherichia coli.
    J Immunol. 1981 Jul;127(1):184-91 PMID: 6787121
  3. Advances in the management of Pseudomonas aeruginosa infections in cancer patients.
    Eur J Cancer. 1973 Jun;9(6):435-41 PMID: 4372050
  4. Type-specific immunity in pseudomonas diseases.
    J Lab Clin Med. 1972 Jan;79(1):47-54 PMID: 4621414
  5. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
    Infect Immun. 1978 Dec;22(3):919-25 PMID: 103841
  6. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.
    J Clin Invest. 1979 Feb;63(2):276-86 PMID: 429553
  7. Pseudomonas bacteremia. Review of 108 cases.
    Am J Med. 1976 Apr;60(4):501-8 PMID: 818897
  8. A new polyvalent Pseudomonas vaccine.
    J Med Microbiol. 1977 Feb;10(1):19-27 PMID: 402473
  9. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
    J Infect Dis. 1972 Sep;126(3):277-87 PMID: 4626510
  10. Immunization against Pseudomonas in infection after thermal injury.
    J Infect Dis. 1974 Nov;130 Suppl(0):S152-8 PMID: 4138646
  11. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.
    J Infect Dis. 1972 Sep;126(3):257-76 PMID: 4626509
  12. Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa.
    Infect Immun. 1978 Dec;22(3):908-18 PMID: 103840
  13. Agar-Gel Precipitating Antibody in Pseudomonas aeruginosa Infections.
    Infect Immun. 1970 Oct;2(4):495-503 PMID: 16557868
  14. Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies.
    Ann Intern Med. 1975 Jun;82(6):819-31 PMID: 806246
  15. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.
    Infect Immun. 1981 Nov;34(2):461-8 PMID: 6171520
  16. Pseudomonas aeruginosa vaccine in cancer patients.
    Ann Intern Med. 1973 Oct;79(4):518-27 PMID: 4201225
  17. Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis.
    Am J Med. 1975 May;58(5):629-36 PMID: 805535
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1982-02-00
Pages
303-8
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC370979
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com